Drug intelligence / Profile preview

Liu Gan Shuang Jie Granule

Development stage: Unknown
Lead developer: Nanjing University of Chinese Medicine
Administration: Oral

Overview

Liu Gan Shuang Jie Granule is a traditional Chinese medicine (TCM) formulation developed by Nanjing University of Chinese Medicine for the treatment of influenza. As a botanical combination therapy, it is designed to alleviate symptoms and potentially exert antiviral effects through the synergistic action of multiple herbal components. In clinical studies, such as the multicenter, double-blind, randomized controlled trial ChiCTR-TRC-12004849, it has been compared against the standard antiviral oseltamivir phosphate to evaluate its clinical efficacy and safety profile in patients with influenza. The formulation is typically administered orally in a granule dosage form.

Other names: Liu Gan Shuang Jie

Beyond the preview

Go deeper on Liu Gan Shuang Jie Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liu Gan Shuang Jie Granule.

Explore the full profile